Yahoo Finance

H.C. Wainwright tells investors in a research note that Compass Pathways (CMPS) is one of the most compelling stories in neuropsychiatry, and that COMP360’s differentiated profile positions it as a “transformative” treatment in treatment-resistant depression. The firm believes the current valuation fails to reflect the full scope of its opportunity across multiple large-market psychiatric disorders with COMP360 on track to become a blockbuster treatment, if approved. The firm reiterates a Buy rating and $45 price target on the shares.

Discover the Best Stocks and Maximize Your Portfolio:

• See what stocks are receiving Strong Buy ratings from top-rated analysts.

• Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See the top stocks recommended by analysts >>

Read More on CMPS:

• COMPASS Pathways: Positioned for Transformative Growth in Neuropsychiatry with COMP360 Advancements

• Optimistic Buy Rating for COMPASS Pathways: Strategic Trials and Strong Financial Position Bolster Confidence in COMP360’s Potential

• Buy Rating for COMPASS Pathways: Promising Phase 3 Trial Progress and Strong Financial Position

• Compass Pathways price target lowered to $15 from $23 at Canaccord

• Compass Pathways Reports 2024 Financial Results and Progress